Skip to content
This GLP
By This GLP Editorial Team · Updated September 2026Starting dose only at $149

PlushCare review

The advertised cash-pay figure buys the 0.25 mg starting dose, and every maintenance dose is priced above it.

The verdict

PlushCare advertises compounded semaglutide at $149 a month cash-pay, and that figure covers the 0.25 mg starting dose only. Every higher dose is $299. No compounded tirzepatide price is published, and insurance is accepted on a separate basis.

Disclosure: This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. How we make money.

Category
GLP-1 telehealth
Molecule
Semaglutide · Tirzepatide
Form
Injection
States
50
From
From $149/mo
Prescription
Required
Compounded
Yes — not FDA-approved

PlushCare sells compounded semaglutide as a weekly injection across fifty states. The cash-pay figures read $149 at 0.25 mg and $299 at every dose from 0.5 mg to 2.4 mg. Its compounded tirzepatide page now redirects to a Mounjaro page with no compounded price. Insurance is accepted as a separate route to treatment.

  1. Who writes the prescription, and what do they see?

    Treatment runs through a clinician visit rather than a form alone, and insurance is billed where it applies. That is a different model from a flat-fee compounding seller with no visit in it. What the visit covers, and how often it repeats, is not published. The two routes are priced separately and a reader chooses one at intake.

    Care is arranged remotely and the prescription follows the visit. The cash-pay figure and the insurance route answer different questions for different readers. A reader with coverage is comparing a copay against $149 rather than comparing sellers. A reader without coverage is comparing $149 against a market where most rates are flat.

  2. What happens when the dose goes up?

    This is the seller's weak point and it is stated plainly. $149 buys 0.25 mg, and 0.25 mg is a four-week starting dose for almost everyone. Every dose from 0.5 mg to 2.4 mg is $299, printed in the same sentence as the entry figure. A reader planning a year should treat $149 as the first month and $299 as the standing rate.

  3. What the price includes

    $149 is real and it is narrow. Sellers charging a flat $199 hold that figure at 2.4 mg, where PlushCare charges $299. No compounded tirzepatide figure is published at all. Insurance may change the semaglutide figure and is settled case by case rather than published.

  4. What it claims, and what it cites

    The semaglutide is compounded, so a pharmacy prepares it and no regulator reviews the finished vial. The published weight-change results for semaglutide came from the approved product at maintenance doses, not at 0.25 mg. A starting dose is a titration step rather than a treatment dose. What four weeks at 0.25 mg produces on its own was not measured as an endpoint.

Where it holds up, and where it does not

  • Strength: Says what the entry figure buys
  • Strength: Insurance accepted as a separate route
  • Strength: Prescription follows a clinician visit
  • Limitation: Maintenance doses cost $299 a month
  • Limitation: No compounded tirzepatide price published

What the evidence says about this kind of treatment

The assessment above is about PlushCare. These are about the drugs it sells, and they are traced to the primary literature.

Right for
A reader with insurance who wants a clinician visit in the loop, and who reads $149 as a starting-dose figure rather than a standing one.
Wrong for
A reader budgeting a year at one rate, because the advertised figure covers 0.25 mg and every dose above it is $299.

The evidence behind what PlushCare prescribes

These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation.

How PlushCare compares

SellerWho it suitsGo
LibertyA reader who wants to know what kind of facility made the vial, and will accept a mid-market rate to get that in writing.See Liberty →
Pallas HealthA reader past the opening quarter who wants check-ins priced in, not billed per visit.See Pallas Health →
Harper MedsA reader who wants a clinician, a prescription and the medication under one charge, with no term to commit to before reaching the published rate.See Harper Meds →
Compare all providers side by side →

More GLP-1 telehealth sellers reviews: VitakeyVital StepVivanta CareVivioMDwelludr.Yes Clinic

Sponsored alternative

SkinnyRx

Readers choosing tirzepatide, the one line with a published standing rate

Check SkinnyRx availability →

Frequently asked

Is $149 what a maintenance dose costs?
No. PlushCare states that the $149 cash-pay figure buys the 0.25 mg starting dose, and that 0.5 mg through 2.4 mg cost $299 a month.
How long does anyone stay at 0.25 mg?
The approved semaglutide schedule holds 0.25 mg for four weeks before the first increase. A reader on that schedule is past the advertised figure by month two.
Does insurance change the price?
Insurance is accepted on a separate basis from the cash-pay figure, and what it leaves a patient to pay is settled case by case rather than published.
Is PlushCare expensive compared with other GLP-1 telehealth sellers?
PlushCare publishes a starting figure of $149/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts PlushCare below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes.
This GLP Editorial TeamPublisher · Updated September 2026

How this was assessed. The four questions above are answered from PlushCare’s own publicly-stated model, against the published editorial methodology. No ratings are fabricated and no first-hand outcomes are claimed. A partnership never changes the assessment — see how we make money.